PAA
JAZZ icon

Peregrine Asset Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History

Peregrine Asset Advisers’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-19,965
Closed -$2.77M – 124
2014
Q1 		$2.77M Buy
+19,965
New +$3.01M 2.14% 16

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Peregrine Asset Advisers's JAZZ Position: Q2 2014 in Review

Peregrine Asset Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2014, closing a stake of 19,965 shares — an estimated $2.77M sold.

Peregrine Asset Advisers first reported a position in JAZZ in Q1 2014 and held it in 1 quarter. The position peaked at $2.77M in Q1 2014. 305 funds tracked by Wall St. Rank hold JAZZ as of Q2 2014.

  • Peregrine Asset Advisers reported no remaining Jazz Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Peregrine Asset Advisers sold 19,965 Jazz Pharmaceuticals shares in Q2 2014, an estimated $2.77M.
  • Peregrine Asset Advisers first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Peregrine Asset Advisers's Jazz Pharmaceuticals position peaked at $2.77M in Q1 2014.
  • 305 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2014.

Based on Peregrine Asset Advisers's 13F filing for Q2 2014, filed 14 Aug 2014.